|
WO2016049677A1
|
|
Method of treating cancer
|
|
WO2015006811A2
|
|
Diagnostic methods
|
|
WO2014161046A1
|
|
Methods of treating diseases characterized by excessive wnt signalling
|
|
WO2014063193A1
|
|
Substituted sulfone-containing tricyclic compounds and uses thereof
|
|
WO2014047673A1
|
|
Structure of insulin in complex with n- and c-terminal regions of the insulin receptor alpha-chain
|
|
WO2013185165A1
|
|
Cd-52 antibodies and their use in determining and enhancing an immune response in a subject
|
|
WO2013071355A1
|
|
Soluble mediator
|
|
WO2013053008A2
|
|
Molecules which bind clec9a
|
|
CN103260641A
|
|
Treatment and prevention of malaria
|
|
NZ609186A
|
|
Novel anti-cancer agents
|
|
WO2012045157A1
|
|
Arih2 regulates dendritic cell activation and autoimmunity
|
|
WO2011153586A1
|
|
Kinase inhibitors
|
|
WO2011029126A1
|
|
Methods and reagents for producing antibodies against autoantigens
|
|
WO2010127399A1
|
|
Gene expression profiles and uses thereof
|
|
WO2010127398A1
|
|
Plasmodial polynucleotides, proteins and uses thereof
|
|
WO2010148422A1
|
|
Compounds and methods for treating parasitic infestations
|
|
CA2755983A1
|
|
Compounds and methods for modulating an immune response
|
|
WO2010037181A1
|
|
Cell therapy and compositions therefor
|
|
KR20110088497A
|
|
Methods and compositions for treating and preventing malaria using an invasion ligand directed to a protease-resistant receptor
|
|
WO2010019995A1
|
|
The erg transcription factor modulation of vascular development
|
